Marcia Sellos-Moura, Ph.D., has broad biopharmaceutical experience in program and portfolio strategy and management, operations planning and execution, and in business development. For over 20 years, Dr. Sellos-Moura has worked across all phases of drug development and in multiple therapeutic areas. To date, she has been instrumental in the approval of four commercial products and the development of more than 25 therapeutic candidates. Prior to joining EyePoint, Dr. Sellos-Moura held various roles in program management, business strategy, and operations at Flagship Pioneering and Pioneering Medicines. She also served as Senior Vice President, Head of Program and Portfolio Management at Orphan Technologies, where she played a key role in the development of preclinical and clinical assets and the sale of the company. She previously held multiple positions of increasing responsibility in program management, operations, bioanalytical development, and biomarker discovery at Shire. Dr. Sellos-Moura began her career as a scientist at Transkaryotic Therapies working on the development of enzyme replacement therapies for rare diseases. She was awarded her Ph.D. in Biochemistry, Cell and Molecular Biology from Cornell University and a graduate degree in Biopharmaceutical International Regulatory Affairs from Northeastern University, has authored multiple manuscripts, and been granted several patents.